649-P: Impact of Early Initiation of Dulaglutide on A1C in Patients with Type 2 Diabetes

Abstract

This retrospective, observational study assessed glycemic control over a 6-month follow-up among patient cohorts with T2D who initiated dulaglutide (DU) 0.75 mg or 1.5 mg following use of either 1, 2 or 3+ oral antihyperglycemic drugs (OAD) during the 24-month pre-index period. This analysis used US claims data from the HealthCore Integrated Research Database (HIRD®) between November 2012 and February 2020 (index date=earliest DU fill between November 2014 and August 2019). Patients ≥18 years old with T2D, ≥1 pharmacy claim for OAD during the pre-index period, continuous enrollment from 24 months pre-index to 6 months post-index date, and ≥1 A1C result within both 6 months pre- and 6 months post-index were included. There were differences in patient characteristics between the cohorts with significant trends (*see figure) of increasing age, comorbidity index scores and pre-index A1C seen with increasing number of prior OADs. Early initiation of DU, proxied by initiation after 1 OAD, resulted in an A1C reduction of 1.39%, and reductions of 1.30% and 1.01% in the 2 OAD and 3+ OAD cohorts, respectively (figure). Greater A1C reductions were observed across subgroups with higher pre-index A1C in each OAD cohort. In this real-world study, a clinically relevant reduction in A1C was seen within 6 months across all cohorts defined by the timing of initiation of DU, with increasing trend of A1C reduction seen with fewer number of prior OADs.View largeDownload slideView largeDownload slide DisclosureM. Hoog: Employee; Self; Eli Lilly and Company, Lilly Diabetes, Stock/Shareholder; Self; Abbott, Eli Lilly and Company, PPD. J. L. Smith: Employee; Self; HealthCore, Other Relationship; Self; Eli Lilly and Company. M. Yu: Employee; Self; Lilly Diabetes, Employee; Spouse/Partner; LifeLabs, Stock/Shareholder; Self; Lilly Diabetes, Stock/Shareholder; Spouse/Partner; Lilly Diabetes. J. Peleshok: Employee; Self; Eli Lilly and Company. R. Mody: Employee; Self; Eli Lilly and Company. M. Grabner: Other Relationship; Self; Eli Lilly and Company.